These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 37714122)
21. Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic. Lim S; Lee S Molecules; 2022 Aug; 27(16):. PubMed ID: 36014340 [TBL] [Abstract][Full Text] [Related]
22. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Aishworiya R; Valica T; Hagerman R; Restrepo B Neurotherapeutics; 2022 Jan; 19(1):248-262. PubMed ID: 35029811 [TBL] [Abstract][Full Text] [Related]
24. Natural Products and Their Therapeutic Effect on Autism Spectrum Disorder. Deb S; Phukan BC; Dutta A; Paul R; Bhattacharya P; Manivasagam T; Thenmozhi AJ; Babu CS; Essa MM; Borah A Adv Neurobiol; 2020; 24():601-614. PubMed ID: 32006376 [TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal problems are associated with increased repetitive behaviors but not social communication difficulties in young children with autism spectrum disorders. Chakraborty P; Carpenter KLH; Major S; Deaver M; Vermeer S; Herold B; Franz L; Howard J; Dawson G Autism; 2021 Feb; 25(2):405-415. PubMed ID: 32972215 [TBL] [Abstract][Full Text] [Related]
26. Psychotropic Drug Treatment Patterns in Persons with Fragile X Syndrome. Dominick KC; Andrews HF; Kaufmann WE; Berry-Kravis E; Erickson CA J Child Adolesc Psychopharmacol; 2021 Dec; 31(10):659-669. PubMed ID: 34818076 [No Abstract] [Full Text] [Related]
27. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Howes OD; Rogdaki M; Findon JL; Wichers RH; Charman T; King BH; Loth E; McAlonan GM; McCracken JT; Parr JR; Povey C; Santosh P; Wallace S; Simonoff E; Murphy DG J Psychopharmacol; 2018 Jan; 32(1):3-29. PubMed ID: 29237331 [TBL] [Abstract][Full Text] [Related]
28. Methylphenidate for children and adolescents with autism spectrum disorder. Sturman N; Deckx L; van Driel ML Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857 [TBL] [Abstract][Full Text] [Related]
30. Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder. Thom RP; Pereira JA; Sipsock D; McDougle CJ Curr Psychiatry Rep; 2021 Oct; 23(12):79. PubMed ID: 34643815 [TBL] [Abstract][Full Text] [Related]
31. Biopsychological correlates of repetitive and restricted behaviors in autism spectrum disorders. Comparan-Meza M; Vargas de la Cruz I; Jauregui-Huerta F; Gonzalez-Castañeda RE; Gonzalez-Perez O; Galvez-Contreras AY Brain Behav; 2021 Oct; 11(10):e2341. PubMed ID: 34472728 [TBL] [Abstract][Full Text] [Related]
32. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Politte LC; Scahill L; Figueroa J; McCracken JT; King B; McDougle CJ Neuropsychopharmacology; 2018 Jul; 43(8):1772-1778. PubMed ID: 29540864 [TBL] [Abstract][Full Text] [Related]
33. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. McDougle CJ; Scahill L; Aman MG; McCracken JT; Tierney E; Davies M; Arnold LE; Posey DJ; Martin A; Ghuman JK; Shah B; Chuang SZ; Swiezy NB; Gonzalez NM; Hollway J; Koenig K; McGough JJ; Ritz L; Vitiello B Am J Psychiatry; 2005 Jun; 162(6):1142-8. PubMed ID: 15930063 [TBL] [Abstract][Full Text] [Related]
34. An open trial of divalproex sodium in autism spectrum disorders. Hollander E; Dolgoff-Kaspar R; Cartwright C; Rawitt R; Novotny S J Clin Psychiatry; 2001 Jul; 62(7):530-4. PubMed ID: 11488363 [TBL] [Abstract][Full Text] [Related]
35. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Aman MG Semin Pediatr Neurol; 2004 Sep; 11(3):225-8. PubMed ID: 15575418 [TBL] [Abstract][Full Text] [Related]
36. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Goel R; Hong JS; Findling RL; Ji NY Int Rev Psychiatry; 2018 Feb; 30(1):78-95. PubMed ID: 29693461 [TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Stepanova E; Dowling S; Phelps M; Findling RL Dialogues Clin Neurosci; 2017 Dec; 19(4):395-402. PubMed ID: 29398934 [TBL] [Abstract][Full Text] [Related]
38. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. Hollander E; Kaplan A; Cartwright C; Reichman D J Child Neurol; 2000 Feb; 15(2):132-5. PubMed ID: 10695900 [TBL] [Abstract][Full Text] [Related]
39. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Silva EAD; Medeiros WMB; Torro N; Sousa JMM; Almeida IBCM; Costa FBD; Pontes KM; Nunes ELG; Rosa MDD; Albuquerque KLGD Trends Psychiatry Psychother; 2022 Jun; 44():e20200149. PubMed ID: 34043900 [TBL] [Abstract][Full Text] [Related]